MedTrace Logo

Study of Subcutaneous Immunoglobulin in Patients With PID Requiring IgG Replacement Therapy

NCT00419341 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2013-01-25

Study results available
· View outcomes & findings →

Summary

The objective of this study is to assess the efficacy, tolerability, safety and pharmacokinetics of IgPro20 in patients with primary humoral immunodeficiency (PID).

Conditions

  • Primary Immune Deficiency

Interventions

BIOLOGICAL

Human Normal Immunoglobulin for Subcutaneous Administration

Sponsors & Collaborators

  • CSL Behring

    lead INDUSTRY

Principal Investigators

  • Richard L. Wasserman, MD, PhD · Dallas Allergy Immunology and Medical City Children's Hospital,

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-11-30
Primary Completion
2008-10-31
Completion
2008-10-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00419341 on ClinicalTrials.gov